Patent Trial and Appeal Board Examines mRNA Technology in COVID-19 Vaccine Dispute

Amid the unfolding legal discussions surrounding mRNA technology’s role in vaccine development, the Patent Trial and Appeal Board (PTAB) hosted a significant exchange on Tuesday. Representatives for pharmaceutical giants Pfizer, BioNTech, and Moderna debated the merits of mRNA-based vaccines, specifically questioning whether the scientific community would have pursued this technology as viable before the onset of the COVID-19 pandemic in 2019. This contentious issue has brought mRNA’s historical perspective into sharp relief, as the companies aim to assert their stances on the innovation’s perceived value before it became instrumental in addressing the global health crisis.